Richard obtained his BSc and MSc both from China. His master’s research mainly focused on photodynamic therapy. After graduation in 2018, he joined a pharmaceutical company that takes a leading role in the manufacturing and research of heparins. Before he joined the Davis Group, he worked as a research assistant at a Hong Kong university, in the area of host-guest chemistry. He is currently working on the design and synthesis of supramolecular antibiotics.